Estramustine phosphate is a nitrogen mustard derivative of estradiol that has been advocated for the treatment of prostatic cancer. The compound was designed with the hope that the estrogen moiety would direct the alkylating moiety to estrogen-dependent malignancies, where the alkylating moiety would be released specifically. Preclinical and clinical data are reviewed to determine to what extent that challenging concept is fulfilled. In addition, we have examined critically the efficacy of this drug for the treatment of prostatic cancer. From available data it appears that there is no evidence that the alkylating moiety of estramustine phosphate is specifically freed in estrogen-dependent tissues. Estramustine phosphate appears to be an active compound with acceptable toxicity in prostatic cancer. However, further clinical trials must be undertaken to clarify the future role of estramustine phosphate in the treatment of prostatic cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0022-5347(17)58499-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer.
Cancer Med
December 2024
Department of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Objective: We aimed to examine trends in novel antiandrogen receptor signal inhibitor (ARSI) usage and medical costs by collecting real-world big data included in The National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open Data, covering most of the clinical practices throughout Japan.
Methods: Usage data for outpatient prescriptions from 2016 to 2021 were extracted from the NDB Open Data. Among the 459,610 million tablets/capsules prescribed, prostate cancer-specific agents (bicalutamide, estramustine phosphate, flutamide, abiraterone, enzalutamide, apalutamide, and darolutamide) were selected to investigate the trends of usage and medical costs.
The relationship between Sjögren's syndrome and recurrent pregnancy loss: a bioinformatics analysis.
Reprod Biomed Online
December 2024
Department of Reproductive Medicine, Lanzhou University Second Hospital, Lanzhou, China. Electronic address:
Article Synopsis
- The study investigates the gene relationships between Sjögren's syndrome, an autoimmune disease, and recurrent pregnancy loss (RPL), suggesting a possible connection between their biological pathways.
- Researchers used gene datasets and advanced analyses (WGCNA and limma) to identify co-expressed genes, leading to the discovery of a shared hub gene, KCNN3, which is up-regulated in both conditions.
- The findings indicate that KCNN3 has links to immune responses and drug sensitivity, and may serve as a potential target for further research on Sjögren's syndrome and RPL.
Synergistic combination effect of the PCA-1/ALKBH3 inhibitor HUHS015 on prostate cancer drugs in vitro and in vivo.
Anticancer Drugs
January 2025
Department of Pharmacy, Laboratory of Chemical Biology, Advanced Medicinal Research Center, Hyogo Medical University, Kobe.
Prostate cancer antigen-1/ALKBH3, a DNA/RNA demethylase of 3-methylcytosine, 1-methyladenine (1-meA), and 6-meA, was found in prostate cancer as an important prognostic factor. Additionally, 1-meA has been associated with other cancers. The ALKBH3 inhibitor HUHS015 was found to be effective against prostate cancer both in vitro and in vivo .
View Article and Find Full Text PDFDose compliance of estramustine phosphate in neoadjuvant chemohormonal therapy combined with degarelix acetate predicts the biochemical recurrence in patients with very high-risk prostate cancer who underwent robot-assisted radical prostatectomy.
Int J Urol
December 2024
Department of Urology, Kobe City Medical Center General Hospital, Kobe, Japan.
Article Synopsis
- The study aimed to assess the safety and effectiveness of neoadjuvant treatment with degarelix acetate and low-dose estramustine phosphate in men with high-/very high-risk prostate cancer before surgery.
- A total of 187 patients participated, with 140 undergoing surgery after receiving 6 months of the treatment, highlighting adverse events, surgical outcomes, and rates of biochemical recurrence.
- Results showed that patients with very high-risk status and those who reduced the dose of estramustine phosphate had lower rates of biochemical recurrence, indicating that maintaining dose compliance may impact survival outcomes in this group.
Gösta Jönsson (1909-1978): A pioneer in the hormonal treatment of prostate cancer in Sweden.
J Med Biogr
August 2024
Department of Laboratory Medicine, Lund University, Lund, Sweden.
Treatment of castration-resistant prostate cancer is and has been a challenge. In 1957, the chemist Imre Könyves came to Sweden as a refugee from Hungary and started to work at AB Leo, a pharmaceutical company in Helsingborg. In 1961, he started to synthesize compounds where the oestrogens were linked to a mustard group by a carbamate.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!